Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer and BioNTech launch Phase 1 study of next-gen BNT162b4 COVID-19 vaccine

By Brian Buntz | November 17, 2022

Pfizer-BioNTechPfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) have begun a Phase 1 study to investigate the next-generation BNT162b4 COVID-19 vaccine candidate that could potentially result in a stronger and more durable immune response.

Known as BNT162b4, the vaccine candidate has a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are conserved across various variants.

The first-generation mRNA-based COVID-19 vaccines encoded the spike protein of the original SARS-CoV-2 virus. The second-generation mRNA-based boosters distributed in the U.S. encode both the spike protein from the original SARS-CoV-2 virus and the BA.4/BA.5 sub-variants.

Earlier this year, Mikael Dolsten, Pfizer’s president of worldwide R&D and medical, said the company aimed to “deliver a next-generation COVID-19 vaccine that can provide durable antibody and T cell immune protection against severe disease and hospitalization for at least one year.”

Dolsten noted that Pfizer intended to “take a stepwise approach by designing and testing different candidates that engage multiple arms of the immune system, including antibodies and T cells.”

While two doses of the first-generation mRNA vaccines initially showed a high efficacy of approximately 95%, the effectiveness of those vaccines waned with time. However, the vaccines continue to offer strong protection against severe disease. The situation led to demand for additional vaccine doses.

“People are now confused about what it means to be fully vaccinated,” Dr. Paul Offitt, director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children’s Hospital of Philadelphia, wrote in NEJM.

Pfizer and BioNTech will investigate BNT162b4 in the U.S. study (NCT05541861), including roughly 180 healthy participants between 18 and 55. Participants in the study will have received at least three prior doses of an mRNA-based COVID-19 vaccine.

The study will test the immune response of BNT162b4 versus the Pfizer-BioNTech BA.4/BA.5-adapted bivalent COVID-19 vaccine.

Although demand for the COVID-19 vaccine is falling, they supercharged Pfizer’s and BioNTech’s revenue in 2021. Between the two companies, sales of the BNT162b vaccine drove $59 billion in revenue last year.

The Pfizer-BioNTech COVID-19 vaccine and booster are among the most popular worldwide.

PFE shares edged up 0.57% to $48.33 in late afternoon trading, while BNTX shares fell 0.41% to $164.23. Shares of Moderna (Nasdaq:MRNA) shares fell 2.18% to $181.22.

In related news, Pfizer and BioNTech announced that their BA.4/BA.5-adapted bivalent booster fared well against novel various omicron variants in neutralizing antibody detection assays.


Filed Under: Infectious Disease
Tagged With: next-gen COVID-19 vaccine, Pfizer-BioNTech COVID-19 vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE